

AMENDMENTS TO THE SPECIFICATION:

**Please replace the paragraph beginning at page 38, line 14, with the following rewritten paragraph:**

0.625 mg of KLH protein is dissolved in ~~0.6~~ 0.6 ml of 10 mM borate buffer, pH 8.8, 150 mM NaCl. To this solution is added 1 mg of human ~~IFN $\alpha$~~  TNF $\alpha$  protein dissolved in 1 ml of the same buffer.

**Please replace the paragraph beginning at page 38, line 30, with the following rewritten paragraph:**

Sequence of the Tat peptide to be used:

Lys-Thr-Ala-Cys-Thr-Asn-Cys-Tyr-Cys-Lys-Lys-Cys-Cys-Phe-His-Cys-Gln-Val-Cys-Phe-Ile-Thr-Lys-Ala-Leu-Gly-Ile-Ser-Tyr-Gly-Arg-Lys (SEQ ID NO: 1).

**Please replace the paragraph beginning at page 63, line 18, with the following rewritten paragraph:**

At day 0, a group of 3 mice (group C) receives a 0.1 ml injection in AIF through intramuscular route containing 60  $\mu$ g of KLH-murine TNF $\alpha$  heterocomplex and 30  $\mu$ g of the phosphorothioate oligodeoxynucleotide 5'-TCCATGACGTTCCCTGACGTT-3' (SEQ ID NO: 2) (CpG ADN: 1826). A booster injection of 30  $\mu$ g and of 15  $\mu$ g of the ~~KKL-murine TNF $\alpha$~~  KLH-murine TNF $\alpha$  heterocomplex in AIF is given respectively at D21 and D60. 3 control mice receive a dosis

equivalent in murine TNF $\alpha$  according to the same protocol[[.]]  
(group D).  

In the Sequence Listing:

          Please insert the attached initial Sequence Listing (in  
paper and computer readable form (CRF)) into the file at the end  
of the specification.